康拓医疗
(688314)
| 流通市值：21.56亿 | | | 总市值：21.56亿 |
| 流通股本：8123.92万 | | | 总股本：8123.92万 |
| 报告期 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 378,532,413.99 | 302,407,498.71 | 320,749,985.21 | 308,934,158.47 |
| 结算备付金 | 0 | 0 | - | - |
| 拆出资金 | 0 | 0 | - | - |
| 衍生金融资产 | 0 | 0 | - | - |
| 应收票据及应收账款 | 5,916,765.08 | 8,467,073.1 | 8,041,643.84 | 5,459,007.91 |
| 其中：应收票据 | 0 | 0 | - | - |
| 应收账款 | 5,916,765.08 | 8,467,073.1 | 8,041,643.84 | 5,459,007.91 |
| 应收款项融资 | 0 | 0 | - | - |
| 预付款项 | 3,903,400.91 | 4,916,187.45 | 5,942,675.94 | 7,642,078.6 |
| 应收保费 | 0 | 0 | - | - |
| 应收分保账款 | 0 | 0 | - | - |
| 应收分保合同准备金 | 0 | 0 | - | - |
| 其他应收款合计 | 3,893,701.26 | 994,296.65 | 1,077,244.37 | 1,019,461.33 |
| 其中:应收利息 | 0 | 0 | - | - |
| 应收股利 | 0 | 0 | - | - |
| 买入返售金融资产 | 0 | 0 | - | - |
| 存货 | 24,750,588.76 | 24,860,222.61 | 24,878,183.59 | 29,995,439.94 |
| 合同资产 | 0 | 0 | - | - |
| 一年内到期的非流动资产 | 0 | 0 | - | - |
| 其他流动资产 | 1,253,725.94 | 1,168,142.55 | 1,108,614.78 | 986,282.47 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 418,250,595.94 | 417,813,421.07 | 416,798,347.73 | 439,036,428.72 |
| 非流动资产: | | | | |
| 发放委托贷款及垫款 | 0 | 0 | - | - |
| 债权投资 | 0 | 0 | - | - |
| 其他债权投资 | 0 | 0 | - | - |
| 长期应收款 | 0 | 0 | - | - |
| 长期股权投资 | 23,537,095.29 | 28,205,211.39 | 32,335,002.13 | 20,039,321.41 |
| 其他权益工具投资 | 3,752,700 | 3,752,700 | 3,752,700 | 3,752,700 |
| 其他非流动金融资产 | 20,000,000 | 20,000,000 | - | - |
| 投资性房地产 | 12,575,547.31 | 12,670,524.79 | 12,765,502.29 | 12,860,479.8 |
| 固定资产 | 125,391,911.77 | 123,698,041.78 | 123,410,702.66 | 123,403,798.38 |
| 在建工程 | 53,869,327.07 | 44,346,579.37 | 35,159,463.16 | 19,437,221.7 |
| 生产性生物资产 | 0 | 0 | - | - |
| 油气资产 | 0 | 0 | - | - |
| 使用权资产 | 8,863,117.57 | 1,480,706.56 | 1,984,311.81 | 2,467,510.36 |
| 无形资产 | 21,634,690.77 | 24,722,310.63 | 25,847,405.74 | 20,417,545.76 |
| 开发支出 | 5,671,784.18 | 4,751,041.82 | 2,895,132.37 | - |
| 商誉 | 6,020,190.86 | 6,020,190.86 | 5,920,936.62 | - |
| 长期待摊费用 | 3,196,042 | 3,615,510.27 | 4,361,159.36 | 4,962,668.91 |
| 递延所得税资产 | 4,097,235.37 | 3,287,107.01 | 3,226,842.36 | 3,223,209.2 |
| 其他非流动资产 | 40,362,624.78 | 43,299,930.03 | 43,328,018.42 | 45,266,782.35 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 328,972,266.97 | 319,849,854.51 | 294,987,176.92 | 255,831,237.87 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 747,222,862.91 | 737,663,275.58 | 711,785,524.65 | 694,867,666.59 |
| 流动负债: | | | | |
| 短期借款 | 0 | 0 | - | - |
| 向中央银行借款 | 0 | 0 | - | - |
| 吸收存款及同业存放 | 0 | 0 | - | - |
| 拆入资金 | 0 | 0 | - | - |
| 交易性金融负债 | 0 | 0 | - | - |
| 衍生金融负债 | 0 | 0 | - | - |
| 应付票据及应付账款 | 25,845,698.39 | 26,968,968.48 | 23,802,260.36 | 16,778,712.23 |
| 其中：应付票据 | 0 | 0 | - | - |
| 应付账款 | 25,845,698.39 | 26,968,968.48 | 23,802,260.36 | 16,778,712.23 |
| 预收款项 | 0 | 0 | - | - |
| 合同负债 | 4,382,585.12 | 4,073,525.88 | 3,421,572.37 | 3,075,461.64 |
| 卖出回购金融资产款 | 0 | 0 | - | - |
| 应付手续费及佣金 | 0 | 0 | - | - |
| 应付职工薪酬 | 12,867,989.73 | 7,447,371.16 | 6,732,804.66 | 7,599,560.19 |
| 应交税费 | 7,880,533.35 | 6,830,338.69 | 9,736,383.12 | 9,172,710.14 |
| 其他应付款合计 | 4,434,767.24 | 4,838,712.33 | 6,476,708.9 | 5,395,825 |
| 其中:应付利息 | 0 | 0 | - | - |
| 应付股利 | 0 | 0 | - | - |
| 应付分保账款 | 0 | 0 | - | - |
| 保险合同准备金 | 0 | 0 | - | - |
| 代理买卖证券款 | 0 | 0 | - | - |
| 代理承销证券款 | 0 | 0 | - | - |
| 一年内到期的非流动负债 | 38,074,506.71 | 37,022,666.7 | 38,082,460.84 | 38,098,677.64 |
| 其他流动负债 | 511,742.48 | 461,151.4 | 389,257 | 363,657.31 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 93,997,823.02 | 87,642,734.64 | 88,641,447.25 | 80,484,604.15 |
| 非流动负债: | | | | |
| 长期借款 | 0 | 0 | - | - |
| 应付债券 | 0 | 0 | - | - |
| 优先股 | 0 | 0 | - | - |
| 永续债 | 0 | 0 | - | - |
| 租赁负债 | 6,998,795.72 | 0 | 128,333.11 | 453,852.73 |
| 长期应付款 | 53,230.1 | 69,177.12 | 67,034.68 | 116,790.8 |
| 长期应付职工薪酬 | 0 | 0 | - | - |
| 预计负债 | 0 | 0 | - | - |
| 递延收益 | 5,505,336.79 | 5,620,426.36 | 5,735,515.93 | 5,850,605.5 |
| 递延所得税负债 | 2,819,595.12 | 3,574,346.36 | 3,869,761.92 | 3,193,280.42 |
| 其他非流动负债 | 0 | 0 | - | - |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 15,376,957.73 | 9,263,949.84 | 9,800,645.64 | 9,614,529.45 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 109,374,780.75 | 96,906,684.48 | 98,442,092.89 | 90,099,133.6 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 81,239,172 | 81,239,172 | 81,239,172 | 81,239,172 |
| 其他权益工具 | 0 | 0 | - | - |
| 优先股 | 0 | 0 | - | - |
| 永续债 | 0 | 0 | - | - |
| 资本公积 | 300,027,849.02 | 300,027,849.02 | 300,027,849.02 | 298,228,632.03 |
| 减:库存股 | 0 | 0 | - | - |
| 其他综合收益 | 1,807,787.49 | 1,695,069.33 | 1,985,737.58 | 1,948,991.13 |
| 专项储备 | 0 | 0 | - | - |
| 盈余公积 | 51,668,296.4 | 39,824,264.91 | 39,824,264.91 | 39,824,264.91 |
| 一般风险准备 | 0 | 0 | - | - |
| 未分配利润 | 200,834,385.3 | 215,615,559.28 | 187,694,552.52 | 184,833,987.97 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 635,577,490.21 | 638,401,914.54 | 610,771,576.03 | 606,075,048.04 |
| 少数股东权益 | 2,270,591.95 | 2,354,676.56 | 2,571,855.73 | -1,306,515.05 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 637,848,082.16 | 640,756,591.1 | 613,343,431.76 | 604,768,532.99 |
| 负债和股东权益合计 | 747,222,862.91 | 737,663,275.58 | 711,785,524.65 | 694,867,666.59 |
| 公告日期 | 2025-03-28 | 2024-10-29 | 2024-08-14 | 2024-04-26 |
| 审计意见(境内) | 标准无保留意见 | | | |